Related Experiment Video
Updated: Nov 13, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
MicroRNA-29a inhibits cell proliferation and arrests cell cycle by modulating p16 methylation in cervical cancer
Anjin Wang1, Qiying Xu2, Rengaowa Sha2
1School of Basic Medical Sciences, Wuhan University, Wuhan, Hubei 430072, P.R. China.
Abstract:
Cervical cancer is the second most common gynecological malignancy. Accumulating evidence has suggested that microRNAs (miRNAs) are involved in the occurrence and development of cervical cancer. The present study aimed to investigate the function and underlying molecular mechanism of microRNA (miRNA/miR)-29a in cervical cancer. Reverse transcription-quantitative PCR and methylation-specific PCR were used to examine the expression of miR-29a and methylated status of p16 promoter, respectively. Cell Counting Kit-8 analysis and flow cytometry were performed to evaluate cell viability and cycle, respectively. Dual-luciferase reporter assay was performed to verify the interaction between miR-29a and its targets. Western blot analysis was performed to detect the protein levels of DNA methyltransferases (DNMT)3A and DNMT3B. The results demonstrated that miR-29a expression was downregulated in cervical cancer tissues and cells, and negatively correlated with p16 promoter hypermethylation. Furthermore, cell experiments confirmed that miR-29a suppressed cell proliferation and induced cell cycle arrest in HeLa and C-33A cells. Mechanically, miR-29a restored normal methylation pattern of the p16 gene by sponging DNMT3A and DNMT3B. Taken together, the results of the present study demonstrated the epigenetic regulation of tumor suppressor p16 by miR-29a as a unique mechanism, thus providing a rationale for the development of miRNA-based strategies in the treatment of cervical cancer.
Insights
MicroRNA-29a (miR-29a) acts as a tumor suppressor in cervical cancer by inhibiting cell proliferation. It restores normal methylation patterns of the p16 gene by targeting DNA methyltransferases, offering a potential therapeutic strategy.
Area of Science:
- Gynecological oncology
- Epigenetics
- Molecular biology
Background:
- Cervical cancer is a major gynecological malignancy.
- MicroRNAs (miRNAs) play a role in cancer development.
- The specific function of miR-29a in cervical cancer requires elucidation.
Purpose of the Study:
- To investigate the role and molecular mechanism of miR-29a in cervical cancer.
- To explore the relationship between miR-29a and p16 promoter methylation.
- To determine the therapeutic potential of miR-29a.
Main Methods:
- Reverse transcription-quantitative PCR to measure miR-29a expression.
- Methylation-specific PCR to assess p16 promoter methylation.
- Cell Counting Kit-8, flow cytometry, dual-luciferase reporter assay, and Western blot to analyze cell behavior and molecular interactions.
Main Results:
- miR-29a expression was significantly downregulated in cervical cancer tissues and cells.
- miR-29a expression negatively correlated with p16 promoter hypermethylation.
- Overexpression of miR-29a suppressed cervical cancer cell proliferation and induced cell cycle arrest.
- miR-29a targeted and inhibited DNA methyltransferases (DNMT3A and DNMT3B), restoring p16 gene methylation.
Conclusions:
- miR-29a functions as a tumor suppressor in cervical cancer.
- miR-29a epigenetically regulates the tumor suppressor gene p16 via DNA methyltransferases.
- miR-29a represents a potential therapeutic target for cervical cancer treatment.
Related Concept Videos
MicroRNAs
MicroRNAs
Negative Regulator Molecules
Abnormal Proliferation
Inhibition of Cdk Activity
Molecular Factors Affecting Cell Division
Several proteins function as internal regulators to ensure each cell cycle stage is completed faithfully before proceeding to the next. Regulator molecules may act directly or influence the activity or production of other...

